01
Name what's in the bottle.
Genus, species, strain ID. On every label. No proprietary blends. No “probiotic complex.”
We didn’t build a probiotic. We built a roadmap.
Metabolica Health is a research-forward bioscience company innovating in the fields of nutraceuticals, probiotics and pharmaceuticals. Our approach is inspired by the microbiome: Probiotics that change the architecture of the gut microbiome and are designed to optimize the production of health-promoting bioactive compounds; and drug candidates that are supercharged enhanced versions of naturally occurring microbiome metabolites.
Our most advanced drug project is focussed on restoring and improving the body’s ability to produce insulin and rebalance metabolism. Unlike current treatments, such as GLP-1 agonists, our approach directly targets the health and function of the pancreas and well as the capacity of cells to respond to insulin. By targeting the disease's biological root, the Metabolica approach regenerates insulin-producing pancreatic β-cells and enhances systemic metabolism. This will lead to weight loss, improved liver health and glucose management.
Backed by peer-reviewed publications, patents in the United States, Canada and the European Union, and global academic partnerships including the University of Paris and Kyoto University, Metabolica is building a scalable therapeutic platform with broad clinical potential and clear translational focus.
In addition to ACREOS™, our drug discovery and development program, we are concurrently developing science based first-in-class next generation probiotic and postbiotic natural health products for applications in metabolic health and other areas.
Metabolica is also advancing holistic nutriceutical plus probiotic products to ensure that the best research-backed approaches are available in a single powerful format for those seeking natural products to support metabolic health, stress resilience, and other areas. The first release of these products is scheduled for Q4 2026.
Our leadership team and science advisory board combine deep scientific expertise with operational and business experience to translate discovery into real-world impact.
01
Genus, species, strain ID. On every label. No proprietary blends. No “probiotic complex.”
02
Not the marketing CFU. Not the minimum-viable CFU. The number the published trials used.
03
Every health statement traces back to a peer-reviewed mechanism. Tagged on the page. Linked to the paper.
Advisory board public, first study published, three formulations defined.
Built around how your microbiome keeps time.
Metabolic balance and stress resilience round out the three-ritual stack.
Canada NPN expansion. Wholesale to clinics and integrative practices.
The leaders steering Metabolica's strategy and governance.

Mr. Fields attended UCB and UCLA as an undergraduate in organic chemistry and then was in a MD/Ph.D. program at University of Southern California. He is a serial entrepreneur who successfully started and managed several companies over the past 40 years.

Dr. Auld brings 20+ years of experience in neuroscience, drug development, and research leadership. He leads operations at McGill's Victor Phillip Dahdaleh Institute of Genomic Medicine (2011–2025), co-holds two patents, and is a graduate of the adMare Executive Academy. He earned his Ph.D. from McGill and has published in leading journals including Nature, Gastroenterology, Nature Genetics and Nature Aging.

Mr. Bonnell has 30 years of leadership in capital, markets, natural resources and venture capital. He holds an LLB (Western Ontario), MSc (LSE), and MBA (McGill) and is a member of the Law Society of Upper Canada.